2929 Pharma Foods International Co., Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

2929

TSE Prime

Pharma Foods International Co., Ltd.

938

JPY

+12

(+1.30%)

Dec 23, 3:30 pm JST

5.98

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul, 2021	46,752	5,673	5,767	3,841	132.2	25	Sep 6, 2021	J-GAAP
Jul, 2022	60,185	1,080	1,264	-374	-12.9	20	Sep 6, 2022	J-GAAP
Jul, 2023	68,572	3,610	3,540	3,081	106.7	22	Sep 11, 2023	J-GAAP
Jul, 2024	62,147	5,113	5,249	3,205	112.7	25	Sep 12, 2024	J-GAAP
Jul, 2025 Guidance	65,000	2,000	2,300	1,600	55.0	25	Sep 12, 2024	J-GAAP
YoY	+4.6%	-60.9%	-56.2%	-50.1%	-51.2%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Jul, 2020	Sep 6, 2019	13,654	689	752	483	0	J-GAAP
-	Jan 14, 2020	13,654	689	752	483	－	J-GAAP
-	Mar 6, 2020	14,500	689	752	523	7	J-GAAP
	Aug 26, 2020	15,353	740	788	690	8.5	J-GAAP
Results	Sep 7, 2020	15,353	740	788	690	8.5	J-GAAP
Jul, 2021	Sep 7, 2020	Available in future release
	Nov 16, 2020
	Feb 8, 2021
	Jul 19, 2021
	Sep 2, 2021
Results	Sep 6, 2021
Jul, 2022	Sep 6, 2021
	Jun 3, 2022
	Sep 5, 2022
Results	Sep 6, 2022
Jul, 2023	Sep 6, 2022
	Jul 18, 2023
Results	Sep 11, 2023
Jul, 2024	Sep 11, 2023
	Mar 11, 2024
	Jul 25, 2024
Results	Sep 12, 2024
Jul, 2025	Sep 12, 2024	65,000	2,000	2,300	1,600	25	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jul, 2001	96	－	Available in future release
Jul, 2002	302	+214.6
Jul, 2003	260	-13.9
Jul, 2004	512	+96.9
Jul, 2005	705	+37.7
Jul, 2006	1,200	+70.2
Jul, 2007	1,107	-7.8
Jul, 2008	810	-26.8
Jul, 2009	734	-9.4
Jul, 2010	959	+30.7
Jul, 2011	1,006	+4.9
Jul, 2012	1,225	+21.8
Jul, 2013	1,524	+24.4
Jul, 2014	1,614	+5.9
Jul, 2015	2,165	+34.1
Jul, 2016	3,460	+59.8
Jul, 2017	4,722	+36.5
Jul, 2018	7,943	+68.2
Jul, 2019	10,532	+32.6
Jul, 2020	15,353	+45.8
Jul, 2021	46,752	+204.5
Jul, 2022	60,185	+28.7
Jul, 2023	68,572	+13.9
Jul, 2024	62,147	-9.4
Jul, 2025 Guidance	65,000	+4.6	2,000	-60.9	2,300	-56.2	55.0	-51.2

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Jul, 2023	68,572	3,610	5.26	36.90	9.14	2.04	106.7
Jul, 2024	62,147	5,113	8.23	30.21	8.80	1.71	112.7
Jul, 2025 Guidance	65,000	2,000	3.08	13.94	4.85	1.97	55.0

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	68,572	5,673	5,767	3,841	132.2
Fiscal Year	Jul, 2023	Jul, 2021	Jul, 2021	Jul, 2021	Jul, 2021

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Aug - Jan, 2021	28,821	2,032	2,105	1,561	53.9	10	Mar 7, 2022	J-GAAP
Aug - Jan, 2022	35,143	-883	-912	-914	-31.6	10	Mar 7, 2023	J-GAAP
Aug - Jan, 2023	31,652	1,535	1,542	768	26.7	10	Mar 11, 2024	J-GAAP
Aug - Jan, 2024 Guidance	ー	ー	ー	ー	－	12.50	Sep 12, 2024	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Jan, 2022	Sep 6, 2021	27,850	1,108	1,119	535	10	J-GAAP
	Mar 3, 2022	28,821	2,032	2,105	1,561	10	J-GAAP
Results	Mar 7, 2022	28,821	2,032	2,105	1,561	10	J-GAAP
Jan, 2023	Sep 6, 2022	Available in future release
Results	Mar 7, 2023
Jan, 2024	Sep 11, 2023
Results	Mar 11, 2024
Jan, 2025	Sep 12, 2024	ー	ー	ー	ー	12.5	J-GAAP

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Jul, 2022	1,080	-8,604	-6,065	-2,539	7,679	8,845	28.39	J-GAAP
Jul, 2023	3,610	5,112	6,125	-1,013	2,341	16,306	45.00	J-GAAP
Jul, 2024	5,113	4,096	5,486	-1,390	-4,842	15,566	42.56	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Aug - Oct, 2022	17,030	-2,194	-2,180	-1,820	-62.8	ー	Dec 5, 2022	J-GAAP
Aug - Oct, 2023	16,142	601	605	286	9.9	39.2	Dec 11, 2023	J-GAAP
Aug - Oct, 2024	14,596	882	888	360	12.9	ー	Dec 11, 2024	J-GAAP
YoY	-9.6%	+46.8%	+46.8%	+25.9%	+29.4%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Nov - Jan, 2022	18,113	1,311	1,268	906	31.3	7.2	Mar 7, 2023	J-GAAP
Feb - Apr, 2023	17,390	2,517	2,494	1,982	68.7	14.5	Jun 5, 2023	J-GAAP
May - Jul, 2023	16,039	1,976	1,958	2,013	69.7	12.3	Sep 11, 2023	J-GAAP
Aug - Oct, 2023	16,142	601	605	286	9.9	3.7	Dec 11, 2023	J-GAAP
Nov - Jan, 2023	15,510	934	937	482	16.7	6.0	Mar 11, 2024	J-GAAP
Feb - Apr, 2024	15,519	1,731	1,681	1,088	38.1	11.2	Jun 10, 2024	J-GAAP
May - Jul, 2024	14,976	1,847	2,026	1,349	47.4	12.3	Sep 12, 2024	J-GAAP
Aug - Oct, 2024	14,596	882	888	360	12.9	6.0	Dec 11, 2024	J-GAAP
YoY	-9.6%	+46.8%	+46.8%	+25.9%	+29.4%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Nov - Jan, 2019	3,362	+28.7	Available in future release
Feb - Apr, 2020	4,660	+73.9
May - Jul, 2020	4,241	+59.2
Aug - Oct, 2020	8,387	+171.4
Nov - Jan, 2020	12,006	+257.1
Feb - Apr, 2021	13,355	+186.6
May - Jul, 2021	13,004	+206.6
Aug - Oct, 2021	12,606	+50.3
Nov - Jan, 2021	16,215	+35.1
Feb - Apr, 2022	15,229	+14.0
May - Jul, 2022	16,135	+24.1
Aug - Oct, 2022	17,030	+35.1
Nov - Jan, 2022	18,113	+11.7
Feb - Apr, 2023	17,390	+14.2
May - Jul, 2023	16,039	-0.6
Aug - Oct, 2023	16,142	-5.2
Nov - Jan, 2023	15,510	-14.4
Feb - Apr, 2024	15,519	-10.8
May - Jul, 2024	14,976	-6.6
Aug - Oct, 2024	14,596	-9.6	882	+46.8	888	+46.8	12.9	+30.3

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	18,113	3,040	3,051	2,288	78.8
Fiscal Year	Jan, 2022	Jul, 2021	Jul, 2021	Jul, 2021	Jul, 2021

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Jul, 2022	243.65	22.7	31,159	7,071	3,300	2.38	Sep 6, 2022	J-GAAP
Jul, 2023	333.88	26.6	36,232	9,630	5,792	2.09	Sep 11, 2023	J-GAAP
Jul, 2024	412.71	31.7	36,573	11,585	8,356	1.46	Sep 12, 2024	J-GAAP
Aug - Oct, 2024	ー	34.8	32,972	11,479	8,296	1.19	Dec 11, 2024	J-GAAP

Pharma Foods International Co., Ltd.(2929) Financial Results